flagship-pioneering
(5)
Moderna Designed Its COVID Vaccine in Two Days. The Hard Part Took Ten Years.
The Cambridge biotech turned messenger RNA from a lab curiosity into a platform for printing medicines from genetic code - vaccines, cancer shots, and rare-disease drugs that share one factory and swap out the instructions.
Ring Therapeutics
Ring Therapeutics is a Cambridge, Massachusetts biotechnology company founded by Flagship Pioneering to build a new class of gene therapy delivery vectors from anelloviruses - the most abundant and diverse family of viruses that naturally and harmlessly live inside the human body. Because these commensal viruses evade the immune system, Ring's AnelloVector platform aims to solve gene therapy's biggest limitations: the inability to re-dose patients, pre-existing immunity, and narrow tissue targeting. Through its Anellogy discovery platform and AnelloBricks in-vitro manufacturing technology, Ring is engineering re-dosable, tissue-specific, scalable vectors intended to carry a wide range of therapeutic payloads.
Vesalius Therapeutics
Vesalius Therapeutics is a Cambridge, Massachusetts biotech founded by Flagship Pioneering that aims to reconceptualize how common diseases are understood and treated. Its premise: illnesses that drive roughly 90% of human disease burden are not single conditions but constellations of genetically and biologically distinct diseases. Vesalius uses AI, human genetics and genomics, and patient-derived iPSC cell models to spot hidden clinical patterns, trace them to causal gene circuits, and discover novel drug targets for conditions like Parkinson's, heart failure, type 2 diabetes, and Alzheimer's.
Ampersand Biomedicines
Ampersand Biomedicines is a Boston-area biotech founded by Flagship Pioneering that builds programmable biologic medicines designed to act only where disease lives. Its computational Address, Navigate, Determine (AND) Platform maps the body for ideal localization targets and designs AND-Body Therapeutics that anchor at a disease site and conditionally switch on biology there, aiming to widen the therapeutic window and cut the off-tissue side effects that limit conventional drugs.
Lila Sciences
Lila Sciences is a Cambridge, Massachusetts company building what it calls scientific superintelligence: an 'AI Science Factory' that fuses generative AI with fully autonomous, robotic laboratories. Its platform generates hypotheses, designs and runs physical experiments, reads the results, and decides what to test next - closing the loop of the scientific method without a human pipetting at every step. Spun out of Flagship Pioneering's labs in 2023 and unveiled from stealth in March 2025, Lila has raised roughly $550 million and reached a valuation around $1.3 billion, with autonomous-science units aimed at life, chemical, and materials science.